Table 6.
The most common adverse effects during esketamine treatment.
| Author, Year | No. of Assessed Patients | Dissociation [%] | Headaches [%] | Dizziness [%] | Vertigo [%] | Nausea [%] | Dysgeusia [%] | Elevation in BP [%] |
|---|---|---|---|---|---|---|---|---|
| Canuso, C.M. 2018 [33] | 35 (DB), 27 (FU) | 31.4 (DB), 0 (FU) | 31.4 (DB), 7.4 (FU) | 34.3 (DB), 3.7 (FU) | 11.4 (DB), 0 (FU) | 37.1 (DB), 0 (FU) | 31.4 (DB), 3.7 (FU) | N/A |
| Daly, E.J. 2018 [26] | 56 (DB), 57 (OL) | 20 (DB) | 21 (DB), 14 (OL) | 36 (DB), 39 (OL) | 7 (DB) | 18 (DB), 16 (OL) | 18 (DB), 23 (OL) | Hypertension-5 (DB) |
| Fedgchin, M. 2019 [34] | 231 | 26.8 | 20.3 | 25.1 | 20.8 | 29.4 | 16.0 | 8.2 |
| Popova, V. 2019 [35] | 116 | 26.1 | 20.0 | 20.9 | 26.1 | 26.1 | 24.3 | 9.6 |
| Daly, E.J. 2019 [36] | 152 | 23.0 | 17.8 | 20.4 | 25.0 | 16.4 | 27.0 | 6.6 |
| Fu, D-J. 2020 [37] | 113 | 29.2 | 18.6 | 35.4 | 6.2 | 20.4 | 14.2 | 16.8 |
| Ochs-Ross, R. 2020 [38] | 72 | 12.5 | 12.5 | 20.8 | 11.1 | 18.1 | 5.6 | 12.5 |
| Takahashi, N. 2021 [39] | 122 | 37.7 | 12.3 | 36.1 | 15.6 | 18.0 | N/A | 41.0 |
| Ionescu, D.F. 2021 [40] | 114 | 38.6 | 21.9 | 41.2 | 6.1 | 33.3 | 25.4 | 6.1 |
Abbreviation: N/A—not applicable; DB—double-blind; FU—follow-up; OL—open label.